Biotie's nepicastat fails US post-traumatic stress disorder study
This article was originally published in Scrip
Executive Summary
Top-line data from a Phase IIa study evaluating Biotie Therapies' dopamine beta hydroxylase inhibitor nepicastat (SYN117) in combat veterans suffering from post-traumatic stress disorder (PTSD) show that the product was not effective in relieving PTSD-associated symptoms when compared to placebo.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.